Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS)

Q: What does CUSIP 171126204 represent in this 13F holders report?

CUSIP 171126204 is the security identifier for PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share in Q4 2025?

15 institutional investors reported PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 171126204

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 3,044,738
Total 13F shares: 899,359
Share change: +436,597
Total reported value: $27,880,129
Price per share: $31.00
Number of holders: 15
Value change: +$13,536,994
Number of buys: 14
Number of sells: 3

Quarterly Holders Quick Answers

What is CUSIP 171126204?
CUSIP 171126204 identifies PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 171126204:

Q1 2026 Q4 2025 Q3 2025

Top shareholders of PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
LIGAND PHARMACEUTICALS INC	13D/G 3/4/5	Ligand Pharmaceuticals Incorporated · Director, 10%+ Owner	50%	5,189,177	$145,296,959	+$7,316,652	06 Nov 2025	13D/G 3/4/5
Todd C. Davis	3/4/5	Director	— mixed-class rows	4,762,953 mixed-class rows	$16,264,921	—	02 Jul 2025	3/4/5
3i, LP	13D/G	—	9.9%	318,886	$8,673,699	+$428,346	31 Dec 2025	13D/G
Murchinson Ltd.	13D/G 13F	Company	9.1%	280,000	$7,840,000	$0	30 Sep 2025	13D/G 13F
Ikarian Capital, LLC	13D/G 13F	Company	8.4%	255,758	$6,534,617	+$1,771,892	31 Dec 2025	13D/G 13F
Scott M. Plesha	3/4/5	CEO and President, Director	— mixed-class rows	422,356 mixed-class rows	$2,117,890	—	02 Jul 2025	3/4/5
VANGUARD GROUP INC	13F	Company	2.2%	66,836	$1,871,408	—	30 Sep 2025	13F
Francis Knuettel II	3/4/5	CFO, Treas & Secty	— mixed-class rows	234,834 mixed-class rows	$1,424,648	—	02 Jul 2025	3/4/5
Sai Rangarao	3/4/5	Chief Commercial Officer	— mixed-class rows	154,036 mixed-class rows	$772,410	—	02 Jul 2025	3/4/5
Alexandra Wood (Canada) Inc.	13D/G	—	9.5%	574,187	$734,959	$0	13 Dec 2024	13D/G
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.7%	21,245	$594,860	—	30 Sep 2025	13F
Richard B. Baxter	3/4/5	Director	— mixed-class rows	96,446 mixed-class rows	$483,623	—	02 Jul 2025	3/4/5
Motif Pharmaceuticals Ltd.	3/4/5	10%+ Owner	— class O/S missing	470,674	$442,434	—	15 Feb 2024	3/4/5
Boswell Prayer Ltd.	3/4/5	10%+ Owner	— class O/S missing	459,895	$432,301	—	15 Feb 2024	3/4/5
Aperture Healthcare Ventures Ltd.	3/4/5	10%+ Owner	— class O/S missing	426,566	$400,972	—	15 Feb 2024	3/4/5
Andrew J. Einhorn	3/4/5	Director	0.39%	12,000	$342,000	—	23 Dec 2025	3/4/5
AME Equities LLC	3/4/5	10%+ Owner	— class O/S missing	351,163	$330,093	—	15 Feb 2024	3/4/5
DIADEMA PARTNERS LP	13F	Company	0.34%	10,498	$293,944	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.34%	10,330	$289,240	—	30 Sep 2025	13F
David M. Knott Jr.	13F	Individual	0.2%	6,112	$171,136	—	30 Sep 2025	13F
Persistent Asset Partners Ltd	13F	Company	0.08%	2,403	$67,284	—	30 Sep 2025	13F
Steward Partners Investment Advisory, LLC	13F	Company	0.06%	1,910	$53,480	—	30 Sep 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.03%	827	$23,156	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0%	137	$3,836	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	11	$308	—	30 Sep 2025	13F
CITIGROUP INC	13F	Company	0%	1	$28	—	30 Sep 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	1	$28	—	30 Sep 2025	13F
Ezra M. Friedberg	13D/G	Ezra Friedberg	8.3%	250,121	—	$0	01 Jul 2025	13D/G
Chia-Lin Simmons	3/4/5	Director	— class O/S missing	235,000	—	—	11 Apr 2025	3/4/5
Eric Lang	3/4/5	Chief Medical Officer	— class O/S missing	154,223	—	—	14 Jun 2024	3/4/5

Institutional Holders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) as of Q4 2025

As of 31 Dec 2025, Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) was held by 15 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 899,359 shares. The largest 10 holders included Murchinson Ltd., Ikarian Capital, LLC, BOOTHBAY FUND MANAGEMENT, LLC, J. Goldman & Co LP, VANGUARD GROUP INC, CANTOR FITZGERALD, L. P., DIADEMA PARTNERS LP, Knott David M Jr, GEODE CAPITAL MANAGEMENT, LLC, and MILLENNIUM MANAGEMENT LLC. This page lists 15 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.